Fenorol (Formoterol) Inhalation Powder

What Is Fenorol and What Is It Used For?

Fenorol belongs to a class of medications known as long-acting beta-2 adrenergic agonists (LABAs). The active ingredient, formoterol fumarate dihydrate, works by selectively stimulating beta-2 adrenergic receptors in the smooth muscle of the bronchi. This activation triggers a cascade of intracellular events, ultimately leading to relaxation of the airway smooth muscle and sustained bronchodilation. Unlike short-acting beta-2 agonists (SABAs) such as salbutamol, which provide quick but brief relief, formoterol provides both a rapid onset of action (within 1–3 minutes) and a prolonged duration of effect lasting approximately 12 hours.

In the treatment of asthma, Fenorol is indicated as add-on maintenance therapy in patients who are not adequately controlled on inhaled corticosteroids (ICS) alone. The Global Initiative for Asthma (GINA) recommends that LABAs should be prescribed exclusively in combination with ICS, as LABA monotherapy in asthma has been associated with an increased risk of serious adverse events, including asthma-related hospitalisation and death. Fenorol is typically prescribed at GINA Step 3 and above, where low-to-medium dose ICS alone is insufficient to achieve adequate symptom control.

For patients with chronic obstructive pulmonary disease (COPD), Fenorol is used as regular maintenance bronchodilator therapy to improve airflow and reduce symptoms such as breathlessness and exercise limitation. In COPD, formoterol may be used as monotherapy or in combination with other maintenance medications including long-acting muscarinic antagonists (LAMAs) and inhaled corticosteroids, as recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.

The inhalation powder formulation delivered via hard capsules is designed for use with a specific dry powder inhaler device. The capsules are not intended to be swallowed. Each capsule contains 12 micrograms of formoterol fumarate dihydrate, which is released as a fine powder when the capsule is pierced in the inhaler device and the patient inhales forcefully through the mouthpiece. This delivery method ensures that the medication is deposited directly in the lungs, where it acts locally with minimal systemic absorption.

It is essential to understand that Fenorol is a maintenance (controller) medication and should not be used as a rescue inhaler for acute episodes of bronchospasm. Patients should always have access to a rapid-acting bronchodilator (such as salbutamol) for the relief of acute symptoms. If the need for rescue medication increases, this may indicate deteriorating disease control, and the patient should seek medical advice promptly.

What Should You Know Before Taking Fenorol?

Contraindications

Fenorol should not be used if you have a known hypersensitivity (allergy) to formoterol fumarate or any of the excipients in the capsule formulation. Additionally, formoterol must not be used as monotherapy in patients with asthma – it should always be prescribed alongside an inhaled corticosteroid (ICS). The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have both issued guidance emphasising this requirement due to the documented risk of serious asthma exacerbations when LABAs are used without concurrent anti-inflammatory therapy.

Fenorol is also not appropriate as the sole or primary treatment for acute bronchospasm or status asthmaticus. These are medical emergencies requiring rapid-acting bronchodilators (SABAs) and potentially systemic corticosteroids, oxygen therapy, and other emergency interventions.

Warnings and Precautions

Before initiating treatment with Fenorol, patients should inform their healthcare provider about any of the following conditions, as dose adjustment or enhanced monitoring may be required:

• Cardiovascular disease: Formoterol may cause increases in heart rate, blood pressure, and QT interval prolongation. Patients with coronary artery disease, cardiac arrhythmias (particularly long QT syndrome), heart failure, or hypertrophic obstructive cardiomyopathy should use formoterol with caution and under close medical supervision.
• Thyrotoxicosis (overactive thyroid): Beta-2 agonists may exacerbate symptoms of thyrotoxicosis, including tachycardia and tremor.
• Diabetes mellitus: Formoterol may cause transient hyperglycaemia. Blood glucose levels should be monitored more frequently when initiating treatment, particularly in patients with poorly controlled diabetes.
• Seizure disorders (epilepsy): Beta-2 agonists may lower the seizure threshold in susceptible individuals.
• Hypokalaemia: Beta-2 agonists can cause significant reductions in serum potassium levels, particularly at higher doses or when combined with other medications that deplete potassium (such as thiazide or loop diuretics, corticosteroids, or theophylline). Severe hypokalaemia can provoke cardiac arrhythmias.
• Phaeochromocytoma: Formoterol should be used with caution in patients with known or suspected phaeochromocytoma.

Pregnancy and Breastfeeding

Pregnancy: There is limited data on the use of formoterol during pregnancy in humans. Animal studies have shown reproductive toxicity at very high systemic exposures, well above therapeutic inhaled doses. Nevertheless, Fenorol should only be used during pregnancy if the expected benefit to the mother justifies the potential risk to the foetus. Poorly controlled asthma itself poses significant risks during pregnancy, including pre-eclampsia, preterm birth, and low birth weight, so maintaining adequate asthma control is essential. The decision to continue or discontinue Fenorol during pregnancy should be made in consultation with a healthcare provider experienced in managing asthma in pregnancy.

Breastfeeding: It is not known whether formoterol is excreted in human breast milk, although it has been detected in the milk of lactating rats. Given the low systemic exposure from inhaled formoterol, it is considered unlikely that clinically significant amounts would reach the nursing infant. The benefits of breastfeeding and the clinical need for Fenorol should be weighed against any potential effects on the breastfed infant. Consult your healthcare provider for individualised advice.

How Does Fenorol Interact with Other Drugs?

Drug interactions with formoterol can be broadly categorised into pharmacodynamic interactions (where the combined effect of two drugs is altered) and pharmacokinetic interactions (where one drug affects the absorption, distribution, metabolism, or excretion of another). Understanding these interactions is critical for safe and effective use of Fenorol, particularly in patients with comorbidities who may be taking multiple medications simultaneously.

Major Interactions

Minor Interactions

Formoterol is primarily metabolised by direct glucuronidation and O-demethylation via CYP2D6 and CYP2C enzymes. However, at therapeutic inhaled doses, systemic levels of formoterol are very low, making clinically significant pharmacokinetic interactions uncommon. Nevertheless, potent inhibitors of CYP2D6 (such as paroxetine or fluoxetine) could theoretically increase plasma levels of formoterol, though this has not been shown to be clinically relevant.

What Is the Correct Dosage of Fenorol?

Fenorol inhalation powder is delivered via hard capsules containing 12 micrograms of formoterol fumarate dihydrate. The capsules must be used with the accompanying dry powder inhaler device and should never be swallowed. The precise dosage depends on the condition being treated, the severity of the disease, and individual patient response.

Adults (18 years and over)

Children and Adolescents (6–17 years)

Elderly Patients

Missed Dose

If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose (less than 6 hours away), skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for the missed one. Taking too much formoterol can increase the risk of side effects, particularly cardiac-related adverse events.

Overdose

Symptoms of formoterol overdose may include exaggeration of the drug's pharmacological effects: tremor, headache, palpitations, tachycardia, nausea, hypokalaemia, hyperglycaemia, and prolongation of the QTc interval. In severe cases, ventricular arrhythmias, metabolic acidosis, and cardiac arrest have been reported. If overdose is suspected, contact your local poison control centre or seek emergency medical attention immediately.

Treatment of overdose is primarily supportive and symptomatic. Cardioselective beta-blockers may be considered with extreme caution, as they carry the risk of bronchospasm. Monitoring of serum potassium, blood glucose, and cardiac rhythm (ECG) is essential. Gastric lavage is not relevant for inhaled overdose.

What Are the Side Effects of Fenorol?

Like all medicines, Fenorol can cause side effects, although not everybody gets them. The side effects of formoterol are primarily related to its beta-2 adrenergic stimulatory activity and are generally dose-dependent. Most adverse effects are mild to moderate in severity and tend to diminish or resolve as the body adjusts to the medication. The following classification uses standard frequency categories as defined by the European Medicines Agency (EMA) and the Council for International Organizations of Medical Sciences (CIOMS).

Beta-2 agonist-related side effects such as tremor and palpitations are most commonly experienced when treatment is first started or when the dose is increased. These typically resolve within a few days to weeks of continued use as the body develops tolerance to these systemic effects. The bronchodilatory effect, importantly, does not diminish in the same way.

Paradoxical bronchospasm is a potentially serious but rare adverse reaction in which breathing suddenly worsens immediately after using the inhaler. If this occurs, stop using Fenorol, use your rescue inhaler immediately, and seek medical attention. Your doctor will assess whether an alternative treatment is needed.

Long-term use of beta-2 agonists at high doses has been associated with metabolic effects including hypokalaemia and transient hyperglycaemia. These effects are more pronounced with oral or intravenous administration than with inhaled formulations. Nevertheless, serum potassium should be monitored in patients at risk (e.g. those taking concurrent diuretics, corticosteroids, or theophylline).

How Should You Store Fenorol?

Proper storage of Fenorol is important to maintain the effectiveness and quality of the medication. Formoterol inhalation powder capsules are hygroscopic (sensitive to moisture), and exposure to humidity can cause the powder to clump, reducing the dose delivered to the lungs and impairing therapeutic efficacy. Following these storage guidelines will help ensure each dose provides its full benefit:

• Temperature: Store at room temperature below 25°C (77°F). Do not freeze.
• Moisture protection: Keep the capsules in the original aluminium blister packaging until immediately before use. Only remove a capsule from the blister when you are ready to take your dose.
• Do not store capsules in the inhaler device: The inhaler device should remain empty between uses. Loading a capsule in advance exposes it to ambient humidity.
• Light protection: Avoid prolonged exposure to direct sunlight.
• Keep out of reach of children: Store the medication in a safe place where children cannot access it.
• Expiry date: Do not use Fenorol after the expiry date printed on the blister and outer carton. The expiry date refers to the last day of the stated month.
• Disposal: Do not dispose of unused medicines via wastewater or household waste. Return unused or expired medications to your pharmacy for safe disposal in accordance with local regulations.

The inhaler device itself should be kept clean and dry. Wipe the mouthpiece with a dry cloth regularly. Do not wash the device with water, as moisture may affect the powder delivery mechanism. Replace the inhaler device as recommended by the manufacturer or your pharmacist.

What Does Fenorol Contain?

Understanding the full composition of a medication can be important, particularly for patients with known allergies or intolerances. Fenorol inhalation powder capsules contain the following components:

Active substance: Each hard capsule contains 12 micrograms of formoterol fumarate dihydrate. Formoterol is a racemic mixture; the (R,R)-enantiomer is responsible for the majority of the pharmacological activity. The fumarate salt form provides good chemical stability and aerosol properties suitable for dry powder inhalation.

Excipient: Lactose monohydrate serves as a carrier in the inhalation powder formulation. Lactose particles act as a vehicle for the micronised formoterol drug particles, facilitating uniform dispersion and aerosolisation upon inhalation. The lactose used in inhalation products is of pharmaceutical grade and contains trace amounts of milk proteins.

The hard capsule shell is typically composed of gelatin or hypromellose (HPMC), with colouring agents that may include titanium dioxide and iron oxide pigments. The specific capsule shell composition may vary between manufacturers. The capsule shells are transparent or semi-transparent to allow visual inspection of the powder contents.